A mass yellow fever vaccination campaign is being launched in Faranah, Guinea, this month, following two confirmed and over 20 suspected cases of the disease. The campaign, which is due to begin on January 26th,will target 60,485 people in the district, following confirmed cases in two 40-year old men and an additional 21 suspected cases, from which three patients died. The Guinea Ministry of Health requested the vaccines from the GAVI-funded global emergency stockpile for yellow fever vaccine, which is managed by the International Co-ordinating Group on Vaccine Provision for Yellow Fever Control (YF-ICG).
Yellow fever vaccine campaign planned after outbreak in Guinea
Listen to this article
A mass yellow fever vaccination campaign is being launched in Faranah, Guinea, this month, following two confirmed and over 20 suspected cases of the disease. The campaign, which is due to begin on January 26th,will target 60,485 people in the district, following confirmed cases in two 40-year old men and an additional 21 suspected cases, from which three patients died. The Guinea Ministry of Health requested the vaccines from the GAVI-funded global emergency stockpile for yellow fever vaccine, which is managed by the International Co-ordinating Group on Vaccine Provision for Yellow Fever Control (YF-ICG).
Keep up with the top pharma business news of the week. On the go.
More from Anti-infective
"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."
PolyPid's D-PLEX100 meets Phase III endpoints this time around, significantly reducing surgical point infections in abdominal colorectal surgery, and is set for a US approval submission early next year.
• By
The company will ramp up manufacturing of its Jynneos vaccine to meet demand in worst-affected African countries and stockpiling richer nations.
• By
2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.
More from Therapeutic Category
"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."
![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.